Gonadorelin vs Tirzepatide
Side-by-side comparison of key properties, dosing, and research.
Sexual Health & LibidoAnti-Aging & Longevity
GonadorelinGLP-1 / Weight Loss Agonists
Tirzepatide- Summary
- Gonadorelin is the synthetic form of endogenous GnRH (gonadotropin-releasing hormone). It stimulates the pituitary to release LH and FSH, maintaining testicular function and testosterone production. Widely used alongside TRT to prevent testicular atrophy and preserve fertility.
- Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist that produces greater weight loss than semaglutide in head-to-head trials. SURMOUNT-1 trial showed average 21% body weight reduction at 72 weeks at the highest dose. Marketed as Mounjaro (diabetes) and Zepbound (obesity).
- Half-Life
- ~2–4 minutes (extremely short); pulsatile dosing required to avoid desensitization
- ~5 days
- Admin Route
- SubQ, Intranasal
- SubQ
- Research
- —
- —
- Typical Dose
- 100 mcg
- 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg
- Frequency
- Twice daily (every 12 hours)
- Once weekly, subcutaneous
- Key Benefits
- Maintains testicular size during TRT
- Preserves fertility and sperm production during testosterone use
- Stimulates endogenous LH/FSH production
- Maintains HPG axis function during exogenous hormone use
- Used for HCG-free TRT protocols
- Helps restart natural testosterone production (PCT)
- Average 21% body weight reduction at highest dose (SURMOUNT-1)
- Superior to semaglutide in head-to-head SURPASS trials
- Dual GIP/GLP-1 mechanism for enhanced metabolic control
- Significant reduction in HbA1c for type 2 diabetes
- Improved cardiovascular risk markers
- Reduces visceral fat preferentially
- FDA-approved for T2DM (Mounjaro) and obesity (Zepbound)
- Weekly dosing
- Side Effects
- Injection site reactions
- Headache
- Nausea at initiation
- Tachycardia (rare)
- +1 more
- Nausea (most common during titration)
- Vomiting
- Diarrhea or constipation
- Abdominal pain
- +3 more
- Stacks With
- —
- —